Abstract is: Carolyn Williamson is a South African virologist and microbiologist who is a professor of medical virology at the University of Cape Town. She is a fellow of the Royal Society of South Africa and the African Academy of Sciences, and a member of the Academy of Science of South Africa. Her research focuses on HIV vaccine development and prevention of the disease.
| human | Q5 |
| P1960 | Google Scholar author ID | 3pcRNQYAAAAJ |
| P166 | award received | Fellow of the African Academy of Sciences | Q63208574 |
| Member of the Academy of Science of South Africa | Q75746002 | ||
| P27 | country of citizenship | South Africa | Q258 |
| P108 | employer | University of Cape Town | Q951305 |
| P734 | family name | Williamson | Q2581264 |
| P735 | given name | Carolyn | Q18091370 |
| Carolyn | Q18091370 | ||
| P1412 | languages spoken, written or signed | English | Q1860 |
| P106 | occupation | virologist | Q15634281 |
| microbiologist | Q3779582 | ||
| P21 | sex or gender | female | Q6581072 |
| Q51967517 | A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice |
| Q35076748 | A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component |
| Q35053133 | A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV) |
| Q45180808 | A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons |
| Q33653774 | A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays |
| Q33389245 | African AIDS vaccine programme for a coordinated and collaborative vaccine development effort on the continent |
| Q34743830 | Alphavirus replicon particles as candidate HIV vaccines |
| Q33320529 | Anaemia in acute HIV-1 subtype C infection |
| Q38936867 | Approaches to the induction of HIV broadly neutralizing antibodies |
| Q37473934 | Association of HIV-specific and total CD8+ T memory phenotypes in subtype C HIV-1 infection with viral set point |
| Q38644317 | Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide |
| Q45155821 | Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons |
| Q36154165 | CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck |
| Q35784745 | CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients |
| Q46401926 | CTL response to HIV type 1 subtype C is poorly predicted by known epitope motifs |
| Q47548873 | Case report: mechanisms of HIV elite control in two African women |
| Q40519749 | Cervicovaginal Inflammation Facilitates Acquisition of Less Infectious HIV Variants |
| Q34706934 | Challenges of diagnosing acute HIV-1 subtype C infection in African women: performance of a clinical algorithm and the need for point-of-care nucleic-acid based testing |
| Q40663802 | Characterization and selection of HIV-1 subtype C isolates for use in vaccine development |
| Q36575637 | Characterization of HIV-1 gag and nef in Cameroon: further evidence of extreme diversity at the origin of the HIV-1 group M epidemic |
| Q43681352 | Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference |
| Q36978861 | Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design |
| Q30485614 | Conserved positive selection signals in gp41 across multiple subtypes and difference in selection signals detectable in gp41 sequences sampled during acute and chronic HIV-1 subtype C infection |
| Q46277881 | Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa |
| Q46558508 | Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C. |
| Q40134111 | Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope |
| Q52589121 | Correction for Anthony et al., "Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope". |
| Q46685654 | Correction for Hraber et al., "Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments". |
| Q42363602 | Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization |
| Q37619109 | DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies |
| Q37843826 | Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study |
| Q43940474 | Defining the human immunodeficiency virus type 1 transmission genetic bottleneck in a region with multiple circulating subtypes and recombinant forms |
| Q43183560 | Degenerate Primer IDs and the birthday problem |
| Q45420516 | Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial |
| Q27644515 | Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies |
| Q35715634 | Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa |
| Q37547306 | Differential impact of magnitude, polyfunctional capacity, and specificity of HIV-specific CD8+ T cell responses on HIV set point |
| Q28247153 | Dual HIV-1 infection associated with rapid disease progression |
| Q40501405 | Early evolution of human leucocyte antigen-associated escape mutations in variable Gag proteins predicts CD4+ decline in HIV-1 subtype C-infected women |
| Q33239623 | Enrolling adolescents in research on HIV and other sensitive issues: lessons from South Africa |
| Q42226393 | Epidemiology of HIV-1 subtypes among men who have sex with men in Cape Town, South Africa |
| Q33328477 | Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study |
| Q36388754 | Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape |
| Q36081789 | Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization |
| Q34295981 | Fluidity of HIV-1-specific T-cell responses during acute and early subtype C HIV-1 infection and associations with early disease progression |
| Q35115599 | Generation and evaluation of clade C simian-human immunodeficiency virus challenge stocks |
| Q35140032 | Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa |
| Q43611862 | Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies |
| Q39284385 | Genetic characterization of HIV before widespread testing of HIV vaccine candidates at a clinical trial site in Pretoria, South Africa |
| Q36049017 | Genital inflammation and the risk of HIV acquisition in women |
| Q35628640 | Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women |
| Q57071746 | HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth |
| Q34674930 | HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial |
| Q34266274 | HIV infection in high school students in rural South Africa: role of transmissions among students |
| Q35955635 | HIV molecular epidemiology: transmission and adaptation to human populations |
| Q48080327 | HIV type 1 subtype C gag and nef diversity in Southern Africa |
| Q35993480 | HIV-1 Superinfection Resembles Primary Infection |
| Q35229572 | HIV-1 replication capacity: Setting the pace of disease |
| Q45391786 | HIV-1 subtype C Pr55gag virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine |
| Q46396523 | Heterosexual transmission of multiple highly conserved viral variants in HIV-1 subtype C-infected seronegative women |
| Q42045579 | Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice |
| Q37033201 | Human immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set point |
| Q34455457 | Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models |
| Q34593647 | Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies |
| Q57478288 | Incidence of HIV‐1 Dual Infection and Its Association with Increased Viral Load Set Point in a Cohort of HIV‐1 Subtype C–Infected Female Sex Workers |
| Q36303623 | Increased memory differentiation is associated with decreased polyfunctionality for HIV but not for cytomegalovirus-specific CD8+ T cells |
| Q36414578 | Intersubtype differences in the effect of a rare p24 gag mutation on HIV-1 replicative fitness |
| Q34055991 | Intra- and inter-clade cross-reactivity by HIV-1 Gag specific T-cells reveals exclusive and commonly targeted regions: implications for current vaccine trials |
| Q46581792 | Investigation of HIV in amniotic fluid from HIV-infected pregnant women at full term |
| Q37643535 | Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide Trial |
| Q33504604 | Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection |
| Q46706224 | Longitudinal analysis of HIV type 1 subtype C envelope sequences from South Africa |
| Q40481024 | Metabolic Syndrome After HIV Acquisition in South African Women. |
| Q34587037 | Multiple HIV-1 infections with evidence of recombination in heterosexual partnerships in a low risk Rural Clinical Cohort in Uganda |
| Q36760049 | Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies |
| Q34613552 | Nef-mediated down-regulation of CD4 and HLA class I in HIV-1 subtype C infection: association with disease progression and influence of immune pressure |
| Q34981309 | No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial |
| Q35974269 | Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection |
| Q38659318 | Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments |
| Q34402041 | Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression |
| Q64063774 | Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies |
| Q34742533 | Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop |
| Q37446986 | Preparing developing countries for efficacy trials |
| Q34736181 | Rapid disease progression in HIV-1 subtype C-infected South African women |
| Q37039116 | Rapid, complex adaptation of transmitted HIV-1 full-length genomes in subtype C-infected individuals with differing disease progression |
| Q34332009 | Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa |
| Q56989563 | Relationship between Levels of Inflammatory Cytokines in the Genital Tract and CD4+Cell Counts in Women with Acute HIV‐1 Infection |
| Q40349815 | Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression |
| Q42233388 | Response to 'single genome amplification and sequencing methods require appropriate thresholds for viral transmission and evolution studies'. |
| Q36119504 | Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants |
| Q36656789 | Short Communication: A Recombinant Variant with Increased Envelope Entry Efficiency Emerged During Early Infection of an HIV-1 Subtype C Dual Infected Rapid Progressor |
| Q35508247 | Short communication decreased incidence of dual infections in South african subtype C-infected women compared to a cohort ten years earlier |
| Q35672336 | South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication |
| Q38567088 | South African HIV-1 vaccine candidates - the journey from the bench to clinical trials |
| Q42225514 | Striking lack of T cell immunodominance in both a multiclade and monoclade HIV-1 epidemic: implications for vaccine development |
| Q37409244 | Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site |
| Q36973948 | Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap |
| Q36376181 | Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa |
| Q35765737 | The HIV-1 Epidemic: Low- to Middle-Income Countries |
| Q36259014 | The PTAP sequence duplication in HIV-1 subtype C Gag p6 in drug-naive subjects of India and South Africa |
| Q61228981 | The Replication-Competent HIV-1 Latent Reservoir is Primarily Established Near the Time of Therapy Initiation: Supplemental Material for Abrahams et al |
| Q36483346 | The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection |
| Q36075112 | The challenges of HIV vaccine development and testing |
| Q35076717 | The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection |
| Q33325923 | Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage |
| Q44430247 | Utilizing nucleic acid amplification to identify acute HIV infection |
| Q39598934 | Vertical HIV transmission in South Africa: translating research into policy and practice |
| Q36497283 | Vertical T cell immunodominance and epitope entropy determine HIV-1 escape |
| Q34216522 | Viral and host factors associated with the HIV-1 viral load setpoint in adults from Mbeya Region, Tanzania |
| Q45451237 | Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa |
| Q35034268 | Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes |
| Q36262823 | Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies |
| Q27025177 | Virological features associated with the development of broadly neutralizing antibodies to HIV-1 |
| Carolyn Williamson | wikipedia | |
| Hausa language (ha / Q56475) | Carolyn Williamson | wikipedia |
| ig | Carolyn Williamson | wikipedia |
Search more.